We came across a bullish thesis on Novo Nordisk A/S on Valueinvesting subreddit by Menu-Quirky. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $50.03 as of July 30th. NVO’s trailing and forward P/E were 13.71 and 12.39, respectively according to Yahoo Finance.
A pharmacist holding a box of Exenatide, used to treat type 2 diabetes.
Novo Nordisk presents a compelling case of a high-quality growth company temporarily priced like a...
